Drugs / ACER-801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05325775 | Mar 2022 → Mar 2023 | — | Acer Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACER-801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05325775 ↗ |